Abundant Gut Bacteria in Crohn's Disease Linked to Spondyloarthritis

High levels of a type of E. coli found in patients with Crohn’s disease triggers inflammation associated with spondyloarthritis, according to a study published in Science Translational Medicine.

For the study, the investigators used flow cytometry to examine gut bacteria in fecal samples derived from patients with inflammatory bowel disease (IBD). Flow cytometry is a technology that uses fluorescent probes to detect immunoglobulin-A (IgA)-coated bacterial species.

The investigators discovered that IgA-coated E. coli were abundant in the fecal samples of patients with both Crohn’s disease and spondyloarthritis. Next, they used patient samples and mouse models to link the bacteria to Th17 cells, which help regulate inflammation in individuals with autoimmune disorders.

“Our findings may allow us to develop diagnostic tools to stratify Crohn’s patients with spondyloarthritis symptoms as well as patients at risk,” said senior author Dr Randy Longman.

The results of the study showed patients with Crohn’s disease and spondyloarthritis had higher levels of TH17 cells and the protein IL-23, which triggers disease activity.

The authors noted that the findings may help physicians choose therapies that target symptoms of both the bowels and joints in this patient population.

“Just sequencing the gut flora gives you an inventory of the bacteria, but does not tell you how they are perceived by the host immune system,” said co-author Dr Kenneth Simpson. “This approach is giving you a functional readout versus just an inventory.

“We knew there was smoke but we didn’t know where the fire was. If we can block the ability of bacteria to induce inflammation, we may be able to kick Crohn’s disease and spondyloarthritis into remission.”

Spondyloarthritis is a type of arthritis that attacks the spine and joints, and can even affect the eyes, intestines, and skin, according to the American College of Rheumatology. Individuals in their teens and 20s––especially males––are most often affected.

“In IBD therapy, this is a step toward precision medicine––to be able to clinically and biologically characterize a subtype of disease and then select the medicine that would best fit the patient with this type of inflammation,” Dr Longman said. “The results of this innovative study will start to inform our decision of which of our available medications will give the best chance of helping the individual patient.”
 
 

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

Hillary Norton, MD, considers the windows of opportunity in managing axial spondyloarthritis to prevent various comorbidities and discusses the goals of therapy.
Megan E.B. Clowse, MD, describes how she counsels and treats patients with an autoimmune disease who want to conceive.
Top news of the day from across the health care landscape.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$